COMP <GO>
LEGN vs INDV // RETURN ON INVESTED CAPITAL (ROIC)
Legend Biotech Corporation (NASDAQ) VS. Indivior Pharmaceuticals Inc. (NASDAQ) • 15-METRIC TALLY: LEGN 6
— INDV 6
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: INDV
LAST: $21.10 (-2.45%) • MKT CAP: $4.21B
roic
9.90%
LAST: $35.37 (+0.34%) • MKT CAP: $4.17B
roic
62.20%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (LEGN VS. INDV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | LEGN | INDV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 80.20% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | 9.90% | 62.20% | -52.30 | INDV | /roic <GO> |
| EV/EBITDA & P/E Valuation | 21.0x | 13.4x | +7.60 | INDV | /valuation <GO> |
| Free Cash Flow Yield | 2.21% | -2.24% | +4.45 | LEGN | /fcf-yield <GO> |
| Operating Margin | 13.90% | 21.10% | -7.20 | INDV | /operating-margins <GO> |
| Net Profit Margin | 10.90% | 16.90% | -6.00 | INDV | /net-margins <GO> |
| Revenue Growth (YoY) | 9.90% | 4.30% | +5.60 | LEGN | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.74 | 3.13 | +0.61 | LEGN | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 5/9 | +3.00 | LEGN | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 59.2 | 52.3 | +6.90 | LEGN | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.04 | 1.15 | -0.11 | INDV | /macro-sensitivity <GO> |
| Forward P/E Multiple | 30.5x | 18.4x | +12.10 | INDV | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $4.21B | $4.17B | $31.9M | LEGN | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | LEGN REV | INDV REV | LEGN GROSS % | INDV GROSS % | LEGN FCF | INDV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | — | $1.24B | — | 80.2% | — | -$93.0M |
| FY 2024 | — | $1.19B | — | 80.6% | — | $7.0M |
| FY 2023 | — | $1.09B | — | — | — | -$349.2M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
LEGN // BETA 1.04
INDV // BETA 1.15